The Prognostic Implication of the BRAF V600E Mutation in Papillary Thyroid Cancer in a Chinese Population

Table 2

Recurrence and HRs for BRAF V600E-positive versus negative in PTC and CPTC patients.

	Recurrence
	BRAF V600E-Positive	BRAF V600E-Negative	Hazard Ratio (HR)		Adjusted HR	value
PTC	83 (8.1%)	5 (3.4%)	2.409 [0.977–5.941]	0.056	3.731 [1.457–9.554]	0.006
CPTC	82 (8.2%)	3 (2.7%)	3.109 [0.982–9.842]	0.054	3.993 [1.239–12.869]	0.020